Fifth Circuit weighs Louisiana bid to restrict telehealth access to mifepristone

The Fifth U.S. Circuit Court of Appeals heard arguments September 9 over Louisiana’s effort to restore an in-person dispensing requirement for mifepristone, but the hearing did not immediately change how the medication may be prescribed or delivered.

No ruling had been issued as of September 14, 2026. The current federal framework remains in effect while the appeal proceeds, allowing certified pharmacies to dispense and ship mifepristone under the FDA’s rules, subject to applicable state law.

What Louisiana is challenging

Louisiana is challenging the FDA’s 2023 changes to the risk evaluation and mitigation strategy, or REMS, for mifepristone. The changes removed the federal in-person dispensing requirement and allowed certified pharmacies to dispense and ship the medication.

The state argues that the policy contributes to mifepristone reaching Louisiana through telehealth and out-of-state providers. Louisiana has also argued that the policy affects state sovereignty and can create Medicaid-related costs.

The FDA and the drug’s manufacturers have challenged Louisiana’s legal standing, arguing that the state has not shown a sufficient connection between the federal dispensing policy and the harms it claims.

Why standing dominated the hearing

The three-judge panel focused on whether Louisiana can use this lawsuit to seek relief against a federal policy that applies beyond the state. The judges questioned whether the FDA is responsible for the conduct Louisiana described when state abortion restrictions, out-of-state providers and shield laws may also determine whether a prescription is filled or mailed.

That question matters because a ruling on standing could determine whether the case reaches the underlying dispute over the FDA’s 2023 decision. If Louisiana lacks standing, the court could end the challenge without deciding whether the agency adequately justified the policy change.

What the FDA rules currently allow

The FDA’s current guidance says patients seeking medication abortion through 10 weeks of gestation are not required to see a health care provider in person before obtaining mifepristone under the federal REMS. Certified pharmacies may dispense the medication, including through mail delivery.

Those federal rules do not override state abortion laws. Providers and patients must still consider the law of the state where the patient is located, along with any applicable shield-law protections for providers in states where abortion remains legal.

How the case reached this point

In a May 1, 2026 opinion, the Fifth Circuit granted Louisiana a stay pending appeal and said, at that preliminary stage, that the state had shown standing and was likely to succeed. The opinion was not a final ruling on the merits.

The Supreme Court later paused the effect of that order. As a result, the FDA’s current prescribing, pharmacy-certification and mail-delivery framework remains operative while the Fifth Circuit considers the appeal.

The litigation is part of a broader set of legal fights involving telehealth abortion, interstate mail delivery and state shield laws. A Fifth Circuit decision could affect providers and patients across state lines, but any future impact would depend on the court’s ruling, further litigation and potentially Supreme Court action. It would not automatically produce a nationwide change without additional legal steps.

What happens next

The next major development is a Fifth Circuit ruling. The court could preserve the current framework, require tighter dispensing rules or send the dispute into another round of appeals.

The case is separate from the FDA’s ongoing review of the mifepristone REMS. The agency began that review in September 2025 and, according to the cited court record, was still collecting data as of April 2026.

Sources

Look for updates to this story

Discover more from Interactive News

Subscribe to get the latest posts sent to your email.